Inpatient recipients of packed red blood cells in a university medical center in Poland in 2018–2019

Piotr F. Czempik1, Aleksandra Spień2, Marta Oleksa2, Dawid Wiśniewski2, Łukasz J. Krzych1

1Department of Anaesthesiology and Intensive Care, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
2Students’ Scientific Society, Department of Anaesthesiology and Intensive Care, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland

Summary

Background: Availability of epidemiologic data on recipients of packed red blood cells (RBCC) is crucial for demand planning and policy development in the blood supply and delivery system, as well as patient blood management (PBM). The obvious limitation of large databases is lack of specific clinical data. We aimed to assess inpatient recipients of RBCC in our institution in the years 2018–2019 to prepare a comprehensive institutional PBM program.

Material and methods: We performed a retrospective analysis of all RBCC recipients in our institution between 1 January 2018 and 31 December 2019. Basic demographic and clinical data of patients who received RBCC were retrieved from hospital electronic health records. We calculated the percentage of hospitalizations with RBCC transfusion, average number of RBCC units transfused during single hospitalization in different hospital departments.

Results: During the study period there were 1312 (1.41%) hospitalizations with RBCC transfusion. The median age of transfused patients (1 hospitalization in a hospital department = 1 patient) was 62 (IQR 45–71) years. Among these patients there were 528 (40.2%) men and 784 (59.8%) women. Among patients who were transfused with at least a single RBCC unit, 33.8% were diagnosed with malignancy and 20.3% with non-malignant gastrointestinal disease or gastrointestinal bleeding. Single RBCC transfusions accounted for 85.4% of all transfusions. RBCC unit were transfused most frequently in patients hospitalized in the intensive care unit (ICU) (44.6% of hospitalizations). In departments of Gastroenterology & Hepatology, ICU, Gastrointestinal Surgery, Gynecology & Obstetrics, 2749 units (68.9%) RBCCs were transfused. In the ICU and surgical departments (gastrointestinal, gynecology & obstetrics, neurosurgery) 53.5% of all RBCCs were transfused.

Conclusions: The results show that more than half of RBCC recipients were patients with primary diagnosis of malignancy, non-malignant gastrointestinal disease, or gastrointestinal bleeding. RBCCs were most frequently transfused in patients hospitalized in the ICU. More
than half of all RBCCs were transfused in patients hospitalized in the ICU and surgical departments. In the development phase of inpatient PBM program particular attention should be focused on the abovementioned groups of patients.

Key words: packed red blood cell transfusion, blood use in hospital wards, patient blood management

Introduction

Availability of epidemiologic data on recipients of packed red blood cells (RBCC) is crucial for demand planning and policy development in the blood supply and delivery system, as well as patient blood management (PBM). Access to large sets of data may be challenging due to fragmented and competitive systems of blood supply and delivery, an example of which are data from some administrative regions in the United States of America [1]. The way to overcome these limitations may be creation of large databases that can be used to carry out observational studies. There are only a few examples of such a large databases, the most recent example comes from Scandinavian countries [2, 3]. The obvious limitation of large databases is lack of specific clinical data. An example of meeting both requirements is a donor-component-recipient database from 4 blood centers and 12 hospitals in the United States [4]. There is another similar database under development in Canada [5]. Moreover, epidemiological data on blood recipients may be useful for strengthening PBM. PBM is a strategy of conserving a patient’s own blood through multiple measures [6]. PBM measures should be aimed at potential recipients of RBCC.

We aimed to assess inpatient recipients of RBCC in our institution in years 2018–2019 in order to prepare a comprehensive institutional PBM program.

Material and methods

We performed a retrospective analysis of all RBCC recipients in our institution between 1 January 2018 and 31 December 2019. Our institution is a large medical center affiliated with a medical university, with 644 hospital beds in two locations. The hospital performs both surgical and non-surgical activity. Gastrointestinal surgery department admits patients scheduled for gastrointestinal oncologic and non-oncologic surgery. Oncologic surgery department is a small unit that admits patients scheduled for oncologic surgery of mostly breast, thyroid and pancreas. Both oncology and clinical oncology departments provide chemotherapy, hormonotherapy, and immunotherapy. Clinical pharmacology department specializes in optimizing pharmacotherapy of chronic conditions. The intensive care unit (ICU) is a mixed medical-surgical department.

Basic demographic and clinical data of patients who received RBCC were retrieved from hospital electronic health records (AMMS, Asseco Medical Management Solutions, Poland): age, sex, primary diagnosis, hospital department, number of RBCC units transfused. As decision to transfuse RBCC could depend on a primary diagnosis or a hospital department where a patient was hospitalized, we assumed that 1 hospitalization in the hospital department corresponded to 1 patient. We categorized primary diagnoses [according to International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10)] into broader groups: malignant tumor (patients not undergoing: surgery, radiotherapy, chemotherapy, hormonotherapy, immunotherapy during hospitalization with RBCC transfusion), gastrointestinal disease, oncologic surgery (gastrointestinal, breast, thyroid), malignancy on chemotherapy/hormonal therapy/immunotherapy (duodenum, breast, pancreas, testis, colon, brain, bladder, lung, stomach, ovary), non-oncologic surgery (gastrointestinal, thyroid), iron-deficiency anemia, medical (diabetes mellitus 2, chronic obstructive pulmonary disease, chronic kidney disease), malignancy on radiotherapy (pharynx, esophagus, larynx, colon, lung, bladder, brain, breast, uterus, cervix, stomach, kidney, sigmoid, rectum), hematological disease requiring RBCC transfusion (non-iron-deficiency anemia, acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma), cardiovascular disease (heart failure, heart arrhythmia, hypertension). We decided on a separate category for iron-deficiency anemia due to its high prevalence and the fact that it should be treated with iron supplementation — not RBCC transfusion. Moreover, our analysis was made with the introduction of PBM program in mind. We calculated the percentage of hospita-
lizations with RBCC transfusion and the average number of RBCC units per hospitalization with RBCC transfusion in different hospital departments during the study period.

Due to the retrospective and observational nature of the study the local bioethics committee waived the requirement for ethical approval (PCN/0022/KB/41/20). All patient data were anonymized.

Results

During the study period there were 92,532 hospitalizations, 33,834 (36.6%) male and 58,698 (63.4%) female. There were 1,312 (1.41%) during which at least a single RBCC unit was transfused. The characteristics of the study population is presented in Table 1.

Table 2 presents the primary diagnoses of the physicians as entered on the RBCC order for transfusion.

Among patients who received at least a single RBCC unit, as much as 33.8% were diagnosed with malignancy [malignant tumor; surgery (oncologic); malignancy (chemotherapy), malignancy (radiotherapy)]. Other diagnoses of patients who were transfused were non-gastrointestinal bleeding, non-oncologic gastrointestinal disease, gastrointestinal bleeding. The patients with these 4 top primary diagnoses, as entered by clinicians in an RBCC order, represented 51.3% of all transfused subjects (Table 2).

The highest number of hospitalizations with RBCC transfusion occurred in the following departments: gastroenterology & hepatology, gynecology & obstetrics, gastrointestinal surgery, ICU. These hospitalizations constituted 63.1% of all hospitalizations with RBCC transfusion. The percentage of hospitalizations with RBCC transfusion was highest in the ICU (44.6%) (Table 3).

The hospital wards responsible for using the highest number of RBCC units were the same 4 departments where the highest number of hospitalizations with RBCC transfusion took place (Table 4). In departments of gastroenterology & hepatology, ICU, gastrointestinal surgery, gynecology & obstetrics, 2,749 units (68.9%) of RBCC were transfused. ICU and surgical specialties (gastrointestinal, gynecology & obstetrics, neurosurgery) used 53.5% of all RBCC units. In the study period there were 3,991 RBCC units transfused during 1,312 hospitalizations with transfusion, which corresponded to a mean number of 3.0 RBCC units per hospitalization. Mean number of RBCC units per hospitalization with RBCC transfusion varied from 1.3 ± 0.5 (Neonatology) to 4.0 ± 4.6 (ICU) (Table 4).

Discussion

In our study the percentage of inpatients who received at least a single unit of RBCC transfusion was 1.41%. These patients were most frequently

| Parameter                        | Value          |
|----------------------------------|----------------|
| Age (IQR) all patients [years]   | 62 (45–71)     |
| Age (IQR) men [years]            | 63 (50–70)     |
| Age (IQR) women [years]          | 61 (44–72)     |
| Sex (male/female) [number, %]    | 528 (40.2)/    |
|                                 | 784 (59.8)     |
| Single unit/multiple unit RBCC  | 1120 (85.4%)/  |
| transfections [number, %]        | 192 (14.6)     |

| Primary diagnosis                      | Hospitalizations [number (%)] |
|---------------------------------------|------------------------------|
| Malignant tumor                       | 263 (20.0)                   |
| Bleeding (non-gastrointestinal)       | 144 (11.0)                   |
| Gastrointestinal disease (non-oncologic) | 136 (10.4)                 |
| Gastrointestinal bleeding             | 130 (9.9)                    |
| Surgery (oncologic)                   | 86 (6.6)                     |
| Malignancy (chemotherapy)             | 81 (6.1)                     |
| Bleeding (pregnancy and postpartum)   | 73 (5.6)                     |
| Infection                             | 61 (4.6)                     |
| Surgery (non-oncologic)               | 42 (3.2)                     |
| Critically ill                        | 40 (3.0)                     |
| Medical                               | 39 (3.0)                     |
| Iron-deficiency anemia                | 37 (2.8)                     |
| Hematological disease                 | 36 (2.7)                     |
| Neonatal                              | 32 (2.4)                     |
| Intracranial bleeding                 | 29 (2.2)                     |
| Stroke (ischemic/hemorrhagic)         | 23 (1.8)                     |
| Benign tumor                          | 21 (1.6)                     |
| Cardiovascular disease                | 14 (1.1)                     |
| Malignancy (radiotherapy)             | 14 (1.1)                     |
| Trauma                                | 9 (0.7)                      |
| Acute coronary syndrome               | 1 (0.1)                      |
Table 3. Percentage of hospitalizations with RBCC transfusions per hospital department

| Hospital department                      | Hospitalization with RBCC [number (%)] | All hospitalizations [number (%)] | Percentage of hospitalizations with RBCC (%) |
|------------------------------------------|----------------------------------------|-----------------------------------|--------------------------------------------|
| Gastroenterology & Hepatology            | 263 (20.0)                             | 8290 (9.0)                        | 3.2                                        |
| Gynecology & Obstetrics                  | 206 (15.7)                             | 7117 (7.7)                        | 2.9                                        |
| Gastrointestinal Surgery                 | 189 (14.4)                             | 2661 (2.9)                        | 7.1                                        |
| Intensive Care Unit                      | 170 (13.0)                             | 381 (0.4)                         | 44.6                                       |
| Clinical Oncology                        | 116 (8.8)                              | 8904 (9.6)                        | 1.3                                        |
| Neurosurgery                             | 93 (7.1)                               | 3571 (3.9)                        | 2.6                                        |
| Autoimmune & Metabolic                   | 79 (6.0)                               | 1844 (2.0)                        | 4.3                                        |
| Clinical Pharmacology                    | 61 (4.7)                               | 1311 (1.4)                        | 4.7                                        |
| Neonatology                              | 34 (2.6)                               | 2212 (2.4)                        | 1.5                                        |
| Radiotherapy                             | 32 (2.4)                               | 1531 (1.7)                        | 2.1                                        |
| Stroke Unit                              | 26 (2.0)                               | 1141 (1.2)                        | 2.3                                        |
| Oncology                                 | 18 (1.4)                               | 4501 (4.9)                        | 0.4                                        |
| Endocrinology & Neuroendocrine Tumors    | 8 (0.6)                                | 3218 (3.5)                        | 0.2                                        |
| Neurology                                | 8 (0.6)                                | 3717 (4.0)                        | 0.2                                        |
| Oncological Surgery                      | 5 (0.4)                                | 1332 (1.4)                        | 0.4                                        |
| Neurological Rehabilitation             | 3 (0.2)                                | 292 (0.3)                         | 1.0                                        |
| Adult Ophthalmology                      | 1 (0.1)                                | 31 633 (34.2)                     | 0.0                                        |
| Total                                    | 1312 (100)                             | 92 532 (100)                      | 1.4                                        |

Table 4. Number of RBCC units transfused during hospitalizations

| Hospital department                      | Transfused RBCC [number (%)] | Hospitalizations with RBCC transfusion [number (%)] | RBCC per hospitalization [mean ± SD] |
|------------------------------------------|-----------------------------|-----------------------------------------------------|------------------------------------------|
| Gastroenterology & Hepatology            | 878 (22.0)                  | 263 (20.0)                                          | 3.3 ± 3.3                                |
| Intensive Care Unit                      | 647 (16.2)                  | 170 (13.0)                                          | 4.0 ± 4.6                                |
| Gastrointestinal Surgery                 | 633 (15.9)                  | 189 (14.4)                                          | 3.2 ± 2.8                                |
| Gynecology & Obstetrics                  | 591 (14.8)                  | 206 (15.7)                                          | 2.8 ± 1.7                                |
| Clinical Oncology                        | 283 (7.1)                   | 116 (8.8)                                           | 2.5 ± 1.2                                |
| Neurosurgery                             | 265 (6.6)                   | 93 (7.1)                                            | 2.8 ± 2.4                                |
| Autoimmune & Metabolic                   | 213 (5.3)                   | 79 (6.0)                                            | 2.7 ± 1.4                                |
| Clinical Pharmacology                    | 187 (4.7)                   | 61 (4.7)                                            | 3.4 ± 2.9                                |
| Stroke Unit                              | 75 (1.9)                    | 26 (2.0)                                            | 2.9 ± 1.6                                |
| Radiotherapy                             | 74 (1.8)                    | 32 (2.4)                                            | 2.3 ± 0.5                                |
| Neonatology                              | 45 (1.1)                    | 34 (2.6)                                            | 1.3 ± 0.5                                |
| Oncology                                 | 42 (1.0)                    | 18 (1.4)                                            | 2.3 ± 1.0                                |
| Neurology                                | 22 (0.6)                    | 8 (0.6)                                             | 2.8 ± 1.4                                |
| Endocrinology & Neuroendocrine Tumors    | 16 (0.4)                    | 8 (0.6)                                             | 2.0 ± 0.0                                |
| Oncological Surgery                      | 11 (0.3)                    | 5 (0.4)                                             | 2.2 ± 1.1                                |
| Neurological Rehabilitation             | 7 (0.2)                     | 3 (0.2)                                             | 2.3 ± 0.6                                |
| Adult Ophthalmology                      | 2 (0.1)                     | 1 (0.1)                                             | 2.0 ± 0.0                                |
| Total                                    | 3991 (100)                  | 1312 (100)                                          | 3.1 ± 2.8                                |

RBCC — packed red blood cells, SD — standard deviation
diagnosed with malignant tumor, non-gastrointestinal bleeding, gastrointestinal disease, gastrointestinal bleeding (Table 2). The percentage of RBCC-transfused inpatients in community-based Kaiser-Permanente database was as high as 13% [7]. The comprehensive data coming from the United States showed that 10.9% of inpatients received at least a single unit of RBCC [8]. The disparity with our study could be related to different mix of hospital departments, different hospital populations, and different periods of time analyzed. It is worth mentioning that in the study period the Regional Blood Transfusion Center supplied adequate amounts of RBCC so the low volumes of RBCC transfused could not be attributed to out-of-hospital reasons.

In the Dutch multicenter study PROTON (Profiles of Transfusion Recipients), covering inpatients from 20 hospitals in the period 1996–2006, patients who received RBCC transfusion were mostly diagnosed with neoplasms (22.2%), circulatory system disorders (21.5%), injury and poisonings (10.5%), digestive system disorders (9.8%), hematological disease (anemia, coagulation defects, purpura) (8.6%) [9, 10]. The primary diagnoses of patients who received the highest number of RBCC units were similar in our study (malignancy; non-oncologic gastrointestinal disease), although different classifications systems were used for disease categorization. In the study by Karafin et al., common primary diagnoses of transfused patients were blood diseases, infectious diseases, neoplasms, cardiovascular diseases, gastrointestinal disease and injury [8]. Primary diagnoses of neoplasm and gastrointestinal disease, as the main indication for transfusion, were in line with our study. Oncologic patients and patients with gastrointestinal diseases represented 44% of all RBCC recipients in our study. It is advisable to introduce causal treatment of anemia as RBCC transfusion may lead to significant complications. RBCC transfusion may be necessary if other measures are not effective. PBM efforts should be particularly focused on these two categories of patients. Avoiding RBCC transfusion is particularly important in oncologic patients as transfusion may potentially decrease chances of remission by affecting the patient’s immune response, stimulating tumor growth, tethering, and dissemination [11]. On the other hand, patients with gastrointestinal disorders may bleed as a result of their primary diagnosis. Bleeding prophylaxis and timely management of bleeding episodes is crucial for this population of patients.

In our study the mean number of RBCC transfused per hospitalization (if performed) was 3.1 ± 2.8 and varied between hospital departments. This number was higher than reported by American Association of Blood Banks (AABB), where the number of whole blood/RBC units per recipient was 2.72 [12].

Currently there is a tendency to use single unit RBCC transfusions as opposed to multiple unit RBCC transfusions in non-bleeding patients. In our study, 85.4% of all RBC transfusion were single unit transfusions. This may be explained by adherence of physicians to strict policy of RBCC transfusions or implementation of informal hospital campaigns promoting single unit RBCC transfusion. In one before-and-after study, single unit transfusion orders increased from 30–50% to 70–80% following education program [13]. The rationale behind single unit transfusion policy is to use the smallest effective dose of RBCC, so following first RBCC transfusion reassessment should be performed, taking into account not only Hb concentration but also symptoms of anemia [14]. Choosing Wisely Canada campaign for reduction of unnecessary tests and treatments in health care summarized evidence in favor of single unit RBCC transfusions as opposed to two unit RBCC transfusions and initiated an educational program. If implemented, the single unit RBCC transfusion policy showed reduction in utilization of RBCC in numerous clinical settings [15, 16].

The number of RBCC units transfused per patient in a ward is influenced by the clinical condition of patients at admission. Almost half of all ICU hospitalizations involved RBCC transfusion, which results from the fact, that critically ill patients are hospitalized there [17, 18].

The hospital departments responsible for using the highest number of RBCC units in our study were gastroenterology & hepatology (22%), ICU (16.2%), gastrointestinal surgery (15.9%), gynecology & obstetrics (14.8%) (Table 4). The report from AABB showed that medical disciplines using the highest number of RBCC units were general medicine (28.5%), surgery (different surgical specialties) (19.9%), hematology/oncology (19.2%), and ICU (12.5%) [12]. The differences between our study and AABB report may be due to our hospital structural organization (no hematology department). Nevertheless surgical specialties and ICU were common users of large numbers of RBCC in both analyses. In our hospital, surgical specialty departments and intensive care used together 53.8% of RBCC units. This points to the need for diag-

https://journals.viamedica.pl/journal_of_transfusion_medicine
nosis and preoperative treatment of anemia. The following measures are recommended in the ICU and surgical departments in order to avoid anemia that requires RBCC transfusion. First, preoperative anemia should be timely diagnosed [19]. For timely diagnosis of etiology of anemia diagnostic algorithms may be followed [20, 21]. Timely diagnosis of preoperative anemia is particularly important if iron/vitamin supplementation is required, as it needs time to take effect. Another useful measure is saving the blood lost into operative field through application of intraoperative blood saving machines [22], or minimizing iatrogenic blood loss through application of arterial in-line blood conservation devices [23, 24]. The important element of ICU PBM is reduction in the number of ordered laboratory tests leading to iatrogenic blood loss and increased risk of anemia and its complications.

Study limitations

Our study has some limitations. Firstly, we did not consider factors that may have affected the decision to transfuse RBCC: clinical signs of anemia, course of the primary disease, etc. We did not analyze transfusions of other blood components (fresh frozen plasma, platelets, cryoprecipitate) at the time of RBCC transfusion. The hospital electronic health records did not provide information on anemia treatment, such as iron, vitamin B12 and/or folate supplementation, administration of erythropoiesis stimulating agents. We did not analyze Hb concentration, so we had no knowledge of the prevalence of preoperative anemia which could have resulted in higher demand for RBCC in the perioperative period.

Conclusions

The results show that more than half of RBCC recipients were patients with primary diagnosis of malignancy, non-malignant gastrointestinal disease, or gastrointestinal bleeding. RBCC units were most frequently transfused to patients hospitalized in the ICU. More than half of all RBCC units were transfused in the ICU and surgical departments. In the development phase of inpatient PBM program particular attention should be focused on the abovementioned groups of patients.

Conflict of interest: none declared

References

1. Murphy MF. The epidemiology of transfusion: where blood goes and why we should care about it. Transfusion. 2017; 57(12): 2821–2823, doi: 10.1111/trf.14385, indexed in Pubmed: 29226371.
2. Edgren G, Rostgaard K, Vasan SK, et al. The new Scandinavian Donations and Transfusions database (SCANDAT2): a blood safety resource with added versatility. Transfusion. 2015; 55(7): 1600–1606, doi: 10.1111/trf.12986, indexed in Pubmed: 25573303.
3. Kleinman S, Glynna SA. Database research in transfusion medicine: The power of large numbers. Transfusion. 2015; 55(7): 1591–1595, doi: 10.1111/trf.13139, indexed in Pubmed: 2617244.
4. Kleinman S, Busch MP, Murphy EL, et al. National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III). The National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III); a research program striving to improve blood donor and transfusion recipient outcomes. Transfusion. 2014; 54(3 Pt 2): 942–955, doi: 10.1111/trf.12488, indexed in Pubmed: 24188564.
5. Chassé M, McIntyre L, Tinmouth A, et al. Clinical effects of blood donor characteristics in transfusion recipients: protocol of a framework to study the blood donor-recipient continuum. BMJ Open. 2015; 5(1): e007412, doi: 10.1136/bmjopen-2014-007412, indexed in Pubmed: 25600255.
6. Meybohm P, Richards T, Ishister J, et al. Patient blood management bundles to facilitate implementation. Transfus Med Rev. 2017; 31(1): 62–71, doi: 10.1016/j.cmr.2016.05.012, indexed in Pubmed: 27313782.
7. Borkent-Raven BA, Janssen MP, van der Poel CL, et al. The PROTON study: profiles of blood product transfusion recipients in the Netherlands. Vox Sang. 2010; 99(1): 54–64, doi: 10.1111/j.1423-0410.2010.01312.x, indexed in Pubmed: 20292179.
8. Borkent-Raven BA, Janssen MP, van der Poel CL, et al. Survival after transfusion in the Netherlands. Vox Sang. 2011; 100(2): 196–203, doi: 10.1111/j.1423-0410.2010.01378.x, indexed in Pubmed: 20726957.
9. Karafin MS, Bruhn R, Westlake M, et al. National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Demographic and epidemiologic characterization of transfusion recipients from four US regions: evidence from the REDS-III recipient database. Transfusion. 2017; 57(12): 2903–2913, doi: 10.1111/trf.14370, indexed in Pubmed: 29067705.
10. Gouhan HA, Elymar M, Radosевич M, et al. Impact of transfusion on cancer growth and outcome. Cancer Growth Metastasis. 2016; 9: 1–8, doi: 10.4137/CGMS.S2797, indexed in Pubmed: 27006692.
11. Yen AW. Blood transfusion strategies for acute upper gastrointestinal bleeding: are we back where we started? Clin Transl Gastroenterol. 2018; 9(4): 150, doi: 10.1038/s41424-018-0019-2, indexed in Pubmed: 29069384.
12. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013; 368(1): 11–21, doi: 10.1056/NEJMoa1211801, indexed in Pubmed: 23281973.
13. Rouhani NH, Escolar GJ, Liu V, et al. Trends in red blood cell transfusion and 30-day mortality among hospitalized patients. Transfusion. 2014; 54: 2678–86, doi: 10.1111/trf.12825, indexed in Pubmed: 25135770.
14. Whitaker, BI., Rajbhandary, S., Harris, A. The 2013 AABB Blood Collection, Utilization, and Patient Blood Management Survey Report. AABB Press.; 2015.
15. Czajka S, Ziębińska K, Marzenko K, et al. Validation of APACHE II, APACHE III and SAPS II scores in in-hospital and one year
mortality prediction in a mixed intensive care unit in Poland: a cohort study. BMC Anesthesiol. 2020; 20(1): 296, doi: 10.1186/s12871-020-01203-7, indexed in Pubmed: 33267777.

16. Fuchs PA, Czech IJ, Krzych IJ. The pros and cons of the prediction game: the never-ending debate of mortality in the intensive care unit. Int J Environ Res Public Health. 2019; 16(18), doi: 10.3390/ijerph16183394, indexed in Pubmed: 31540201.

17. Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013; 30(6): 270–382, doi: 10.1097/EJA.0b013e32835f4d5b, indexed in Pubmed: 23656742.

18. Muñoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017; 72(2): 233–247, doi: 10.1111/anae.13773, indexed in Pubmed: 27996866.

19. Czempik P, Czepczor K, Czok M, et al. Simplified diagnostic algorithm for classification of preoperative anaemia based on complete blood count and its application in elective gastrointestinal surgery. Pol Przegl Chir. 2019; 91(4): 24–28, doi: 10.5604/01.3001.0013.2569, indexed in Pubmed: 31481643.

20. Pluta M, Klociek T, Krzych IJ. Diagnostic accuracy of red blood cell distribution width in predicting in-hospital mortality in patients undergoing high-risk gastrointestinal surgery. Anaesthesiol Intensive Ther. 2018; 50(4): 277–282, doi: 10.5603/AIT.a2018.0037.

21. Carless PA, Henry DA, Moxey AJ, et al. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2003(4): CD001888, doi: 10.1002/14651858.CD001888, indexed in Pubmed: 14583940.

22. Mukhopadhyay A, Yip HS, Prabhuswamy D, et al. The use of a blood conservation device to reduce red blood cell transfusion requirements: a before and after study. Crit Care. 2010; 14(1): R7, doi: 10.1186/cc8859, indexed in Pubmed: 20105285.

23. Page C, Retter A, Wyncoll D. Blood conservation devices in critical care: a narrative review. Ann Intensive Care. 2013; 3: 14, doi: 10.1186/2110-5820-3-14, indexed in Pubmed: 23714376.

24. Witosz K, Wojnarowicz O, Krzych IJ. Iatrogenic blood loss due to daily laboratory testing and the risk of subsequent anaemia in intensive care unit patients: case series. Acta Biochim Pol. 2021; 68(1): 135–138, doi: 10.18388/abp.2020_5525, indexed in Pubmed: 33682399.